Acute Ischemic stroke results from a sudden cessation of adequate amounts of blood reaching parts of the brain. Ischemic strokes can be divided according to territory affected or mechanism. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, the more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.

 

DelveInsight’s “Acute ischemic stroke Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Acute ischemic stroke (AIS), historical and forecasted epidemiology as well as the Acute ischemic stroke (AIS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Acute ischemic stroke Market Report:

• In November 2020, AstraZeneca, a global, science-led biopharmaceutical company, announced that its product Brilinta (an oral, reversible, direct-acting P2Y12 receptor antagonist) got approval in the U.S. by the U.S. Food and Drug Administration (FDA) to reduce the risk of stroke, a leading global cause of disability and death, in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).
• In 2019, Biogen (a company that discovers, develops, and delivers innovative therapies for neurological and neurodegenerative diseases) signed an exclusive option agreement with TMS Co., Ltd. (a clinical stage biotechnology company) to acquire TMS-007 and backup compounds. TMS-007 is a plasminogen activator with a novel mechanism of action associated with the breakdown of blood clots for people who have had an acute ischemic stroke (AIS).
• This stroke accounts for around 87 percent of the total cases of stroke and uncontrolled hypertension is the key cause contributing to ischemic stroke. 

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market 

 

Scope of the Acute ischemic stroke Market Report

• The report covers the descriptive overview of Acute ischemic stroke (AIS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Acute ischemic stroke (AIS) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Acute ischemic stroke (AIS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Acute ischemic stroke (AIS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute ischemic stroke (AIS) market

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market 

 

Some of Acute Ischemic Stroke Companies are:

• Tasly Pharmaceutical
• AstraZeneca
• Guangzhou Recomgen Biotech
• Supergene
• Healios
• Abbvie
• DiaMedica Therapeutics
• Jeil Pharmaceutical
• Lumosa Therapeutics
• Pharmazz
• Teijin Pharma Limited
• Acticor Biotech
• aptaTargets
• Meridigen Biotech
• DiaMedica therapeutics
• NoNO Inc
• Daiichi Sankyo Company
• Genentech
• Shin Poong Pharmaceutical
• And Many Others

 

 

Some of Acute Ischemic Stroke Therapies are:

• Recombinant human urokinase
• Ticagrelor
• SP-8203
• rhTNK-tPA/rt-PA
• tenecteplase
• Recombinant staphylokinase
• HLCM051
• DS 1040
• Elezanumab
• Recombinant human tissue kallikrein
• JPI-289
• LT3001
• JTR-161
• ACT017
• ApTOLL
• UMC119-06
• DMI 199
• And Many Others

 

Table of Contents:

1. Key Insights

2. Executive Summary of Acute ischemic stroke (AIS)

3. Competitive Intelligence Analysis for Acute ischemic stroke (AIS)

4. Acute ischemic stroke (AIS): Market Overview at a Glance

4.1. Acute ischemic stroke (AIS) Total Market Share (%) Distribution in 2019

4.2. Acute ischemic stroke (AIS) Total Market Share (%) Distribution in 2032

5. Acute ischemic stroke (AIS): Disease Background and Overview

6. Patient Journey

7. Acute ischemic stroke (AIS) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Acute ischemic stroke (AIS) Treatment and Management

8.2. Acute ischemic stroke (AIS) Treatment Algorithm

9. Acute ischemic stroke (AIS) Unmet Needs

10. Key Endpoints of Acute ischemic stroke (AIS) Treatment

11. Acute ischemic stroke (AIS) Marketed Products

List to be continued in report

12. Acute ischemic stroke (AIS) Emerging Therapies

List to be continued in report

13. Acute ischemic stroke (AIS): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Acute ischemic stroke (AIS)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life science. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market